ClinicalTrials.gg
TerminatedNCT00626197BELONGUpdated Dec 22, 2020Results posted

A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)

A Phase 3 interventional study of Corticosteroids and Cyclophosphamide in Lupus Nephritis and Systemic Lupus Erythematosus, sponsored by Genentech, Inc.. Terminated. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2020-12-22.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment

Why this study was terminated
Study was terminated due to an imbalance of serious and opportunistic infections in the ocrelizumab treated patients versus the placebo arm.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
381
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Lupus Nephritis by Hoffmann-La Roche — 2 open to participants now, 3 under way, 1 of them phase 3. Lupus Nephritis · Hoffmann-La Roche.

Enrollment
Largest of 11
381 · median 52
Started
2008
the only one that year
Phase 3
7 of 11
none open now
Registered
5th of 11
by date

Among the 11 studies in Lupus Nephritis by Hoffmann-La Roche, this one has the largest enrollment, is the only one that started in 2008, is one of 7 in phase 3, and was the 5th registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 136 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

2 of the 11 studies in Lupus Nephritis by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Lupus Nephritis by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This is a Phase III, randomized, double-blind, placebo-controlled, multicentre, parallel-group study designed to evaluate the efficacy and safety of ocrelizumab added to SOC (corticosteroid plus one of two immunosuppressant regimens) compared with placebo added to SOC in patients with WHO or ISN Class III or IV lupus nephritis.

03

Conditions studied

  • Lupus Nephritis
  • Systemic Lupus Erythematosus

Keywords

  • SLE
  • Lupus
  • BELONG
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 16 years or above at the time of the screening
  • Ability and willingness to provide written and to comply with the schedule of protocol requirements
  • Diagnosis of SLE
  • Active lupus nephritis

Exclusion criteria

Exclusion Criteria:

  • Currently active retinitis, poorly controlled seizure disorder, acute confusional state, myelitis, stroke or stroke syndrome, cerebellar ataxia, or dementia
  • Severe renal impairment
  • Lack of peripheral venous access
  • Pregnancy or breast feeding mothers
  • History of severe allergic or anaphylactic reactions to humanized, chimeric or murine monoclonal antibodies or i.v. immunoglobulin
  • Known severe chronic pulmonary disease
  • Evidence of significant uncontrolled concomitant diseases in any organ system not related to SLE, which, in the investigator's opinion, would preclude patient participation
  • Concomitant condition which has required treatment with systemic (excluding topical or inhaled steroids) prior to screening
  • Known or chronic active or chronic active infection
  • Known active infection of any kind prior to Day 1
  • History of serious recurrent or chronic infection
  • History of cancer, including solid tumors, hematological and carcinoma in situ (except basal cell carcinoma of the skin that has been excised and cured).
  • History of alcohol or drug abuse prior to screening
  • Major surgery prior to screening, excluding diagnostic surgery
  • Previous treatment with CAMPATH-1H
  • Previous treatment with a BAFF directed treatment (e.g. anti-BLyS) prior to screening
  • Previous treatment with a B-cell targeted therapy other than one directed at BAFF (e.g. anti-CD20, anti-CD22)
  • Treatment with any agent prior to screening
  • Receipt of any prior to Day 1
  • Intolerance or to oral or i.v. corticosteroids
  • Positive hepatitis BsAg or hepatitis C serology. Patients who are HBsAg negative but HBcAb positive may be enrolled with a negative DNA test
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
381 participants (actual)

Study arms

  • Experimental
    OCR 400 mg + SOC

    Participants received Ocrelizumab 400 mg i.v. infusion on Days 1 and 15, followed by 400 mg i.v. at Week 16 and then every 16 weeks plus SOC regimen.

    Drug: Corticosteroids · Drug: Cyclophosphamide · Drug: Mycophenolate Mofetil · Drug: Ocrelizumab · Drug: Azathioprine

  • Experimental
    OCR 1000 mg + SOC

    Participants received Ocrelizumab 1000 mg i.v. infusion on Days 1 and 15, followed by 1000 mg i.v. at Week 16 and then every 16 weeks plus SOC regimen.

    Drug: Corticosteroids · Drug: Cyclophosphamide · Drug: Mycophenolate Mofetil · Drug: Ocrelizumab · Drug: Azathioprine

  • Placebo comparator
    Placebo + SOC

    Participants received placebo i.v. infusion on Days 1 and 15, followed by placebo infusion at Week 16 and then every 16 weeks plus SOC regimen.

    Drug: Corticosteroids · Drug: Cyclophosphamide · Drug: Mycophenolate Mofetil · Drug: Placebo · Drug: Azathioprine

Interventions

  • DrugCorticosteroids

    Intravenous and oral repeating dose

  • Cyclophosphamide was administered at a IV dose 500 mg every 2 weeks for up to 6 doses followed by maintenance treatment with azathioprine.

  • Mycophenolate Mofetil was administered orally at maximum dose of 3 g/day.

  • Ocrelizumab was administed at a dose and as per schedule in arm description

  • DrugPlacebo

    Placebo was administered as per schedule in arm description

  • Azathioprine was administered at a dose up to 2 mg/kg/day with a maximum dose of 200 mg.

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Achieved Complete Renal Response (CRR)

    CRR was defined as: 1. Normal serum creatinine (and with no more than a 25 percent \[%\] increase from Baseline); 2. Improvement in urinary protein:urinary creatinine ratio to less than or equal to (≤) 0.5. PRR was defined as at least 50 percent (%) reduction in proteinuria from Baseline, without more than 25% increase of serum creatinine at Week 48, compared with Baseline. If Baseline urine protein:urine creatinine ratio was greater than (\>) 3, a urine protein:urine creatinine ratio of less than (\<) 3 needed to be achieved.

    Time frame: Week 48

  2. Percentage of Participants Who Achieved Overall Response

    Overall response rate (ORR) equals (=) CRR + PRR. CRR was defined as: 1. Normal serum creatinine (and with no more than a 25% increase from baseline) 2. Improvement in urinary protein:urinary creatinine ratio to ≤0.5. PRR was defined as at least 50 % reduction in proteinuria from Baseline, without more than 25% increase of serum creatinine at Week 48, compared with Baseline. If Baseline urine protein:urine creatinine ratio is \>3, a urine protein:urine creatinine ratio of \<3 needs to be achieved.

    Time frame: Week 48

Secondary outcomes

  1. Percentage of Participants Who Achieved a Renal Response (Partial or Complete) by Week 36, and Sustain or Improve This Response Until Week 48

    Time frame: Weeks 36, 40, 44, and 48

  2. Time To Complete Renal Response

    Time to complete renal response was proposed to be analyzed using a stratified log rank test with race and SOC as stratification factors. Comparisons of ocrelizumab versus placebo were to be expressed as p-values, estimated hazard ratios, adjusted proportions of participants who achieved a complete renal response and their 95% confidence intervals. Kaplan-Meier curves were to be produced. Due to early termination of the study the analyses were not performed.

    Time frame: Baseline up to Week 48

  3. Area Under the Curve (AUC) of Calculated Glomerular Filtration Rate (cGFR) Between Baseline and Week 48

    The improvement of AUC of cGFR was to be measured between Baseline and Week 48. This was to be analyzed with Analysis of Covariance (ANCOVA) with race and SOC as covariates.

    Time frame: Baseline and Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and Week 48

  4. Percentage of Participants Who Achieved A Reduction In Systemic Lupus Erythematosis Disease Activity Index (SLEDAI) -2K Score

    SLEDAI-2K measures disease activity at the visit or within the preceding 10 days. It comprised of 24 descriptors, covering 9 organ systems, and reflects disease activity over the previous 10 days.The total SLEDAI-2K score falls between 0 and 105, with higher scores representing higher disease activity

    Time frame: Baseline and Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48

  5. Time to First Renal Flare In Those Participants Who Demonstrated at Least a Partial Renal Response

    Renal flares may be either proteinuric or nephritic as defined below: Proteinuric Flares are defined as follows:In participants who achieve a urine protein:urine creatinine (Upr:Ucr) ≤ 0.5, an increase to Upr:Ucr \>1; In participants with an Upr:Ucr \>0.5, a doubling of Upr:Ucr (with a minimum increase to Upr:Ucr \>2). Nephritic Flare defined as: Increase in serum creatinine of ≥30% from the lowest value achieved in the study accompanied by Increase Upr:Ucr \>1 Or New/worsening active urine sediment on two consecutive occasions, in the absence of urinary tract infection or other causes of hematuria.

    Time frame: Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48

  6. Percentage of Participants Who Achieved Clinically Meaningful Improvement in the Physical and Mental Component Scores of the Short Form 36 (SF36) From Baseline to Week 48

    The SF36 Health Survey is a 36-item, patient-reported survey of patient health. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale. A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. The eight sections are: vitality, physical functioning, bodily pain, general health perceptions physical role functioning, emotional role functioning, social role functioning, and mental health.

    Time frame: Baseline and Weeks 1, 12, 24, 36, and 48

  7. Percentage of Participants Who Achieved Clinically Meaningful Improvement in Fatigue Using the Functional Assessment of Chronic Illness Therapy (Facit) Fatigue Questionnaire From Baseline to Week 48

    The FACIT Fatigue Scale is a short, 13-item, easy-to-administer tool that measures an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a four point Likert scale (4 = not at all fatigued to 0 = very much fatigued).

    Time frame: Baseline and Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48

  8. Percentage of Participants Who Achieved Clinically Meaningful Improvement in Pain Using the Modified Brief Pain Inventory Short Form (mBPI-SF) From Baseline to Week 48

    m-BPI-sf is a self-administered 11-point Likert rating scale to rate pain in the past 24 hours. A single item pertains to worst pain in the past 24 hours with a range of 0 (no pain) to 10 (worst imaginable pain).

    Time frame: Baseline and Weeks 1, 12, 24, 36, and 48

  9. Health Care Visits Over the 48-Week Treatment Period

    The number of health care visits (including doctor's office visits, Emergency room/ Accident and Emergency \[ER/A\&E\] visits and hospitalizations) over the 48-week treatment period were recorded.

    Time frame: Weeks 1, 24, and 48

  10. Percentage of Participants Who Achieved a CRR or PRR And Who Received A Corticosteroid Dose of <10 Milligrams Per Day (mg/Day) From Week 24 to Week 48

    CRR was defined as: 1. Normal serum creatinine (and with no more than a 25% increase from Baseline) 2. Inactive urinary sediment 3. Improvement in urinary protein:urinary creatinine ratio to ≤0.5. PRR was defined as at least 50% reduction in proteinuria from Baseline, without more than 25% increase of serum creatinine at Week 48, compared with Baseline. If Baseline urine protein:urine creatinine ratio was \>3, a urine protein:urine creatinine ratio of \<3 needed to be achieved.

    Time frame: Week 48

  11. Percentage of Participants Who Achieved a CRR or PRR And Who Received a Corticosteroid Dose of <5 mg/Day by Week 48

    CRR was defined as: 1. Normal serum creatinine (and with no more than a 25% increase from Baseline) 2. Inactive urinary sediment 3. Improvement in urinary protein:urinary creatinine ratio to ≤0.5. PRR was defined as at least 50% reduction in proteinuria from Baseline, without more than 25% increase of serum creatinine at Week 48, compared with Baseline. If Baseline urine protein:urine creatinine ratio was \>3, a urine protein: urine creatinine ratio of \<3 needed to be achieved.

    Time frame: Week 48

  12. Average Corticosteroid Burden Measured by AUC of the Cumulative Corticosteroid Dose Between 16 and 48 Weeks

    AUC is the area under the curve (mathematically known as definite integral) in a plot of concentration of drug in blood plasma against time. AUC was to be used to determine the average corticosteroid burden.

    Time frame: Weeks 16, 20, 24, 28, 32, 36, 40, 44, and 48

  13. Percentage of Participants Who Stopped Immunosuppressants After Week 48

    The number of participants who stopped immunosuppressants were to be determined by survey.

    Time frame: Week 48

  14. Mean Absolute Counts of Cluster of Differentiation (CD) 19 Positive (+) Cells Per Visit

    CD19 is a cell surface molecule which assembles with the antigen receptor of B lymphocytes. It is a critical signal transduction molecule that regulates B lymphocyte development, activation, and differentiation. CD19+ cells were measured as cells per microliter (cells/uL).

    Time frame: Baseline, Day 15, Week 4, 16, 32, 48, and by infusion (pre and post infusion) on Day 1, 15, Week 16, 32

  15. Percentage of Participants With CD19+ Absolute B Cell Counts <10 Cells Per Microliter (Cells/uL)

    CD19 is a cell surface molecule which assembles with the antigen receptor of B lymphocytes. It is a critical signal transduction molecule that regulates B lymphocyte development, activation, and differentiation. 0 represents 0% of participants.

    Time frame: Baseline, Day 15, Week 4, 16, 32, 48, and by infusion (pre and post infusion) on Day 1, 15, Week 16, 32

  16. Percentage of Participants With CD19+ Absolute B Cell Counts <20 Cells/uL by Visit

    CD19 is a cell surface molecule which assembles with the antigen receptor of B lymphocytes. It is a critical signal transduction molecule that regulates B lymphocyte development, activation, and differentiation. n = number of participants analyzed at the specified visit. 0 represents 0% of participants.

    Time frame: Baseline, Day 15, Week 4, 16, 32, 48, and by infusion (pre and post infusion) on Day 1, 15, Week 16, 32

  17. Percentage of Participants With CD19+ Absolute B Cell Counts Less Than the Lower Limit of Normal (LLN) by Visit

    CD19 is a cell surface molecule which assembles with the antigen receptor of B lymphocytes. It is a critical signal transduction molecule that regulates B lymphocyte development, activation, and differentiation. \<LLN = 80 cells/uL.

    Time frame: Baseline, Day 15, Week 4, 16, 32, 48, and by infusion (pre and post infusion) on Day 1, 15, Week 16, 32

  18. Percentage of Participants Achieving a Major Clinical Response or a Partial Clinical Response

    A major clinical response was defined as British Isles Lupus Assessment Group (BILAG) C scores or better at Week 24 without developing any new A or two new B scores up to Week 24 and maintenance of this response without developing a moderate or severe flare between Week 24 and Week 48. A partial clinical response was defined as BILAG C scores or better at Week 24 and maintaining this response without developing a flare for 16 consecutive weeks. The BILAG is an organ-specific 86-question assessment based on the principle of the doctor's intent to treat, which requires an assessment of improved (1), the same (2), worse (3), or new (4) over the last month. Within each organ system, multiple manifestations and laboratory tests are combined into a single score for that organ. The resulting scores for each organ can be A through E, where A is very active disease, B is moderate activity, C is mild stable disease, D is resolved activity, and E indicates the organ was never involved.

    Time frame: Baseline and Weeks 1, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48

07

Results

Posted Dec 22, 2020
Limitations and caveats
The study was terminated early due to an imbalance in serious infections in ocrelizumab-treated participants versus placebo-treated participants. Only 139 of the 381 participants randomized completed the 48 week treatment period.

Participant flow

Screening was done from Day -14 to Day -1.

Participant flow — Overall Study
MilestoneOCR 400 mg + SOCOCR 1000 mg + SOCPlacebo + SOC
Started127128126
Completed837449
Not completed445477
Withdrew: Did not cooperate261
Withdrew: Failure to return656
Withdrew: Adverse event, serious fatal366
Withdrew: Adverse event112
Withdrew: Withdrawal by subject17177
Withdrew: Administrative reasons151955

Outcome measures

PrimaryNumber of Participants Who Achieved Complete Renal Response (CRR)

CRR was defined as: 1. Normal serum creatinine (and with no more than a 25 percent \[%\] increase from Baseline); 2. Improvement in urinary protein:urinary creatinine ratio to less than or equal to (≤) 0.5. PRR was defined as at least 50 percent (%) reduction in proteinuria from Baseline, without more than 25% increase of serum creatinine at Week 48, compared with Baseline. If Baseline urine protein:urine creatinine ratio was greater than (\>) 3, a urine protein:urine creatinine ratio of less than (\<) 3 needed to be achieved.

Time frame:
Week 48
Reported as:
Number · Percentage of Participants
Number of Participants Who Achieved Complete Renal Response (CRR)
Percentage of ParticipantsOCR 400 mg + SOCOCR 1000 mg + SOCPlacebo + SOC
CRR42.731.534.7
PRR2435.620
PrimaryPercentage of Participants Who Achieved Overall Response

Overall response rate (ORR) equals (=) CRR + PRR. CRR was defined as: 1. Normal serum creatinine (and with no more than a 25% increase from baseline) 2. Improvement in urinary protein:urinary creatinine ratio to ≤0.5. PRR was defined as at least 50 % reduction in proteinuria from Baseline, without more than 25% increase of serum creatinine at Week 48, compared with Baseline. If Baseline urine protein:urine creatinine ratio is \>3, a urine protein:urine creatinine ratio of \<3 needs to be achieved.

Time frame:
Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved Overall Response
Percentage of ParticipantsOCR 400 mg + SOCOCR 1000 mg + SOCPlacebo + SOC
Percentage of Participants Who Achieved Overall Response66.7 (56 to 77.3)67.1 (56.3 to 77.9)54.7 (43.4 to 65.9)
SecondaryPercentage of Participants Who Achieved a Renal Response (Partial or Complete) by Week 36, and Sustain or Improve This Response Until Week 48
Time frame:
Weeks 36, 40, 44, and 48

No measurements were reported for this outcome.

SecondaryTime To Complete Renal Response

Time to complete renal response was proposed to be analyzed using a stratified log rank test with race and SOC as stratification factors. Comparisons of ocrelizumab versus placebo were to be expressed as p-values, estimated hazard ratios, adjusted proportions of participants who achieved a complete renal response and their 95% confidence intervals. Kaplan-Meier curves were to be produced. Due to early termination of the study the analyses were not performed.

Time frame:
Baseline up to Week 48

No measurements were reported for this outcome.

SecondaryArea Under the Curve (AUC) of Calculated Glomerular Filtration Rate (cGFR) Between Baseline and Week 48

The improvement of AUC of cGFR was to be measured between Baseline and Week 48. This was to be analyzed with Analysis of Covariance (ANCOVA) with race and SOC as covariates.

Time frame:
Baseline and Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and Week 48

No measurements were reported for this outcome.

SecondaryPercentage of Participants Who Achieved A Reduction In Systemic Lupus Erythematosis Disease Activity Index (SLEDAI) -2K Score

SLEDAI-2K measures disease activity at the visit or within the preceding 10 days. It comprised of 24 descriptors, covering 9 organ systems, and reflects disease activity over the previous 10 days.The total SLEDAI-2K score falls between 0 and 105, with higher scores representing higher disease activity

Time frame:
Baseline and Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48

No measurements were reported for this outcome.

SecondaryTime to First Renal Flare In Those Participants Who Demonstrated at Least a Partial Renal Response

Renal flares may be either proteinuric or nephritic as defined below: Proteinuric Flares are defined as follows:In participants who achieve a urine protein:urine creatinine (Upr:Ucr) ≤ 0.5, an increase to Upr:Ucr \>1; In participants with an Upr:Ucr \>0.5, a doubling of Upr:Ucr (with a minimum increase to Upr:Ucr \>2). Nephritic Flare defined as: Increase in serum creatinine of ≥30% from the lowest value achieved in the study accompanied by Increase Upr:Ucr \>1 Or New/worsening active urine sediment on two consecutive occasions, in the absence of urinary tract infection or other causes of hematuria.

Time frame:
Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48

No measurements were reported for this outcome.

SecondaryPercentage of Participants Who Achieved Clinically Meaningful Improvement in the Physical and Mental Component Scores of the Short Form 36 (SF36) From Baseline to Week 48

The SF36 Health Survey is a 36-item, patient-reported survey of patient health. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale. A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. The eight sections are: vitality, physical functioning, bodily pain, general health perceptions physical role functioning, emotional role functioning, social role functioning, and mental health.

Time frame:
Baseline and Weeks 1, 12, 24, 36, and 48

No measurements were reported for this outcome.

SecondaryPercentage of Participants Who Achieved Clinically Meaningful Improvement in Fatigue Using the Functional Assessment of Chronic Illness Therapy (Facit) Fatigue Questionnaire From Baseline to Week 48

The FACIT Fatigue Scale is a short, 13-item, easy-to-administer tool that measures an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a four point Likert scale (4 = not at all fatigued to 0 = very much fatigued).

Time frame:
Baseline and Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48

No measurements were reported for this outcome.

SecondaryPercentage of Participants Who Achieved Clinically Meaningful Improvement in Pain Using the Modified Brief Pain Inventory Short Form (mBPI-SF) From Baseline to Week 48

m-BPI-sf is a self-administered 11-point Likert rating scale to rate pain in the past 24 hours. A single item pertains to worst pain in the past 24 hours with a range of 0 (no pain) to 10 (worst imaginable pain).

Time frame:
Baseline and Weeks 1, 12, 24, 36, and 48

No measurements were reported for this outcome.

SecondaryHealth Care Visits Over the 48-Week Treatment Period

The number of health care visits (including doctor's office visits, Emergency room/ Accident and Emergency \[ER/A\&E\] visits and hospitalizations) over the 48-week treatment period were recorded.

Time frame:
Weeks 1, 24, and 48

No measurements were reported for this outcome.

SecondaryPercentage of Participants Who Achieved a CRR or PRR And Who Received A Corticosteroid Dose of <10 Milligrams Per Day (mg/Day) From Week 24 to Week 48

CRR was defined as: 1. Normal serum creatinine (and with no more than a 25% increase from Baseline) 2. Inactive urinary sediment 3. Improvement in urinary protein:urinary creatinine ratio to ≤0.5. PRR was defined as at least 50% reduction in proteinuria from Baseline, without more than 25% increase of serum creatinine at Week 48, compared with Baseline. If Baseline urine protein:urine creatinine ratio was \>3, a urine protein:urine creatinine ratio of \<3 needed to be achieved.

Time frame:
Week 48

No measurements were reported for this outcome.

SecondaryPercentage of Participants Who Achieved a CRR or PRR And Who Received a Corticosteroid Dose of <5 mg/Day by Week 48

CRR was defined as: 1. Normal serum creatinine (and with no more than a 25% increase from Baseline) 2. Inactive urinary sediment 3. Improvement in urinary protein:urinary creatinine ratio to ≤0.5. PRR was defined as at least 50% reduction in proteinuria from Baseline, without more than 25% increase of serum creatinine at Week 48, compared with Baseline. If Baseline urine protein:urine creatinine ratio was \>3, a urine protein: urine creatinine ratio of \<3 needed to be achieved.

Time frame:
Week 48

No measurements were reported for this outcome.

SecondaryAverage Corticosteroid Burden Measured by AUC of the Cumulative Corticosteroid Dose Between 16 and 48 Weeks

AUC is the area under the curve (mathematically known as definite integral) in a plot of concentration of drug in blood plasma against time. AUC was to be used to determine the average corticosteroid burden.

Time frame:
Weeks 16, 20, 24, 28, 32, 36, 40, 44, and 48

No measurements were reported for this outcome.

SecondaryPercentage of Participants Who Stopped Immunosuppressants After Week 48

The number of participants who stopped immunosuppressants were to be determined by survey.

Time frame:
Week 48

No measurements were reported for this outcome.

SecondaryMean Absolute Counts of Cluster of Differentiation (CD) 19 Positive (+) Cells Per Visit

CD19 is a cell surface molecule which assembles with the antigen receptor of B lymphocytes. It is a critical signal transduction molecule that regulates B lymphocyte development, activation, and differentiation. CD19+ cells were measured as cells per microliter (cells/uL).

Time frame:
Baseline, Day 15, Week 4, 16, 32, 48, and by infusion (pre and post infusion) on Day 1, 15, Week 16, 32
Reported as:
Mean · Cells/uL
Mean Absolute Counts of Cluster of Differentiation (CD) 19 Positive (+) Cells Per Visit
Cells/uLPlacebo + SOCOCR 400 mg + SOCOCR 1000 mg + SOCOCR + SOCPlacebo-Mycophenolate Mofetil (MMF)Placebo-Euro Lupus (EL)
Baseline203.5 ± 191.4256.3 ± 300.2224.1 ± 231.7240.8 ± 268.9213.7 ± 201.7186.3 ± 175
Day 15262.7 ± 273.91.9 ± 1.92.2 ± 3.42 ± 2.7327.4 ± 324.9163.3 ± 115.8
Week 4209.7 ± 221.41.4 ± 2.51.3 ± 1.61.4 ± 2.1253.4 ± 263.9143.3 ± 107.4
Week 16125.9 ± 186.92.6 ± 3.62 ± 3.82.3 ± 3.7154.3 ± 222.274.7 ± 75.3
Week 32116.6 ± 154.37.8 ± 25.82.1 ± 2.75.1 ± 18.8141.2 ± 172.568.5 ± 96.8
Week 48110 ± 114.311.7 ± 43.62.6 ± 8.97.3 ± 32.2134.9 ± 123.361.3 ± 75
Day 1 Pre-infusion203.5 ± 191.4256.3 ± 300.2222.8 ± 230.2240 ± 268213.7 ± 201.7186.3 ± 175
Day 1 Post-infusion103.1 ± 115.111.1 ± 28.65.7 ± 8.58.4 ± 21.3102.4 ± 114.3104.3 ± 118.6
Day 15 Pre-infusion264.4 ± 276.61.9 ± 1.92.1 ± 3.32 ± 2.7322.5 ± 323.5164.5 ± 118
Day 15 Post-infusion91.2 ± 109.21 ± 1.30.9 ± 1.40.9 ± 1.3106.3 ± 130.865.8 ± 50.4
Week 16 Pre-infusion127.8 ± 190.12.5 ± 3.32.1 ± 3.92.3 ± 3.6156.5 ± 226.376.3 ± 76.5
Week 16 Post-infusion52.7 ± 72.61.2 ± 1.60.8 ± 11 ± 1.364.2 ± 8330.9 ± 40.2
Week 32 Pre-infusion125 ± 161.15.1 ± 16.52 ± 2.73.6 ± 11.8153.4 ± 180.672.2 ± 100.4
Week 32 Post-infusion46.2 ± 54.41 ± 1.50.7 ± 1.40.9 ± 1.456.9 ± 62.527.6 ± 29.5
SecondaryPercentage of Participants With CD19+ Absolute B Cell Counts <10 Cells Per Microliter (Cells/uL)

CD19 is a cell surface molecule which assembles with the antigen receptor of B lymphocytes. It is a critical signal transduction molecule that regulates B lymphocyte development, activation, and differentiation. 0 represents 0% of participants.

Time frame:
Baseline, Day 15, Week 4, 16, 32, 48, and by infusion (pre and post infusion) on Day 1, 15, Week 16, 32
Reported as:
Number · Percentage of Participants
Percentage of Participants With CD19+ Absolute B Cell Counts <10 Cells Per Microliter (Cells/uL)
Percentage of ParticipantsPlacebo + SOCOCR 400 mg + SOCOCR 1000 mg + SOCOCR + SOCPlacebo-Mycophenolate Mofetil (MMF)Placebo-Euro Lupus (EL)
Baseline4.34.21.52.96.80
Day 154.510097.198.67.50
Week 44.498.510099.37.30
Week 164.395.897.196.56.70
Week 327.491.895.693.68.94.3
Week 485.988.798.593.44.48.7
Day 1 Pre-infusion4.34.21.52.96.80
Day 1 Post-infusion1081.283.882.5143.7
Day 15 Pre-infusion4.410097.198.670
Day 15 Post-infusion7.510010010011.90
Week 16 Pre-infusion4.597979770
Week 16 Post-infusion11.510010010012.59.5
Week 32 Pre-infusion3.393.795.294.45.10
Week 32 Post-infusion1510010010010.522.7
SecondaryPercentage of Participants With CD19+ Absolute B Cell Counts <20 Cells/uL by Visit

CD19 is a cell surface molecule which assembles with the antigen receptor of B lymphocytes. It is a critical signal transduction molecule that regulates B lymphocyte development, activation, and differentiation. n = number of participants analyzed at the specified visit. 0 represents 0% of participants.

Time frame:
Baseline, Day 15, Week 4, 16, 32, 48, and by infusion (pre and post infusion) on Day 1, 15, Week 16, 32
Reported as:
Number · Percentage of Participants
Percentage of Participants With CD19+ Absolute B Cell Counts <20 Cells/uL by Visit
Percentage of ParticipantsPlacebo + SOCOCR 400 mg + SOCOCR 1000 mg + SOCOCR + SOCPlacebo-Mycophenolate Mofetil (MMF)Placebo-Euro Lupus (EL)
Baseline7.111.337.311.40
Day 157.610098.599.3103.8
Week 410.310010010012.27.4
Week 1611.498.698.698.613.38
Week 3213.293.210096.515.68.7
Week 4817.691.598.594.913.326.1
Day 1 Pre-infusion7.111.337.211.40
Day 1 Post-infusion22.98791.289.120.925.9
Day 15 Pre-infusion7.410098.699.39.34
Day 15 Post-infusion17.910010010021.412
Week 16 Pre-infusion10.498.598.598.511.68.3
Week 16 Post-infusion4110010010032.557.1
Week 32 Pre-infusion8.395.210097.610.34.8
Week 32 Post-infusion3510010010026.350
SecondaryPercentage of Participants With CD19+ Absolute B Cell Counts Less Than the Lower Limit of Normal (LLN) by Visit

CD19 is a cell surface molecule which assembles with the antigen receptor of B lymphocytes. It is a critical signal transduction molecule that regulates B lymphocyte development, activation, and differentiation. \<LLN = 80 cells/uL.

Time frame:
Baseline, Day 15, Week 4, 16, 32, 48, and by infusion (pre and post infusion) on Day 1, 15, Week 16, 32
Reported as:
Number · Percentage of Participants
Percentage of Participants With CD19+ Absolute B Cell Counts Less Than the Lower Limit of Normal (LLN) by Visit
Percentage of ParticipantsPlacebo + SOCOCR 400 mg + SOCOCR 1000 mg + SOCOCR + SOCPlacebo-Mycophenolate Mofetil (MMF)Placebo-Euro Lupus (EL)
Baseline27.136.633.33529.523.1
Day 1528.81001001003026.9
Week 439.71001001003940.7
Week 1657.110010010048.972
Week 3252.997.310098.635.687
Week 4851.597.210098.537.878.3
Day 1 Pre-infusion27.136.632.834.829.523.1
Day 1 Post-infusion55.797.110098.5.559.3
Day 15 Pre-infusion30.010010010032.628
Day 15 Post-infusion58.210010010052.468
Week 16 Pre-infusion56.710010010048.870.8
Week 16 Post-infusion80.310010010072.595.2
Week 32 Pre-infusion5098.410099.230.885.7
Week 32 Post-infusion88.310010010084.295.5
SecondaryPercentage of Participants Achieving a Major Clinical Response or a Partial Clinical Response

A major clinical response was defined as British Isles Lupus Assessment Group (BILAG) C scores or better at Week 24 without developing any new A or two new B scores up to Week 24 and maintenance of this response without developing a moderate or severe flare between Week 24 and Week 48. A partial clinical response was defined as BILAG C scores or better at Week 24 and maintaining this response without developing a flare for 16 consecutive weeks. The BILAG is an organ-specific 86-question assessment based on the principle of the doctor's intent to treat, which requires an assessment of improved (1), the same (2), worse (3), or new (4) over the last month. Within each organ system, multiple manifestations and laboratory tests are combined into a single score for that organ. The resulting scores for each organ can be A through E, where A is very active disease, B is moderate activity, C is mild stable disease, D is resolved activity, and E indicates the organ was never involved.

Time frame:
Baseline and Weeks 1, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48

No measurements were reported for this outcome.

Adverse events

Collected over Baseline up to 19 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo + SOC6/125 (4.8%)36/125 (28.8%)96/125 (76.8%)
OCR 1000 mg + SOC6/127 (4.7%)38/127 (29.9%)91/127 (71.7%)
OCR 400 mg + SOC3/126 (2.4%)53/126 (42.1%)101/126 (80.2%)
Most frequent serious events
Showing 10 of 130
Most frequent serious events
EventPlacebo + SOCOCR 1000 mg + SOCOCR 400 mg + SOC
PneumoniaInfections and infestations2/1258/1274/126
CellulitisInfections and infestations1/1252/1275/126
NeutropeniaBlood and lymphatic system disorders1/1255/1272/126
Urinary Tract InfectionInfections and infestations1/1252/1274/126
Systemic lupus erythematosusMusculoskeletal and connective tissue disorders3/1252/1273/126
ErysipelasInfections and infestations3/1250/1270/126
AnaemiaBlood and lymphatic system disorders1/1250/1273/126
AgranulocytosisBlood and lymphatic system disorders0/1253/1271/126
Herpes zosterInfections and infestations0/1253/1271/126
Chest painGeneral disorders2/1250/1270/126
Most frequent other events
Showing 10 of 32
Most frequent other events
EventPlacebo + SOCOCR 1000 mg + SOCOCR 400 mg + SOC
DiarrhoeaGastrointestinal disorders22/12532/12726/126
Urinary tract infectionInfections and infestations13/12518/12724/126
Upper respiratory tract infectionInfections and infestations19/12523/12722/126
LeukopeniaBlood and lymphatic system disorders7/12512/12718/126
NasopharyngitisInfections and infestations16/12513/12717/126
Infusion related reactionInjury, poisoning and procedural complications11/12517/12714/126
NeutropeniaBlood and lymphatic system disorders6/1257/12715/126
HeadacheNervous system disorders11/12511/12715/126
BronchitisInfections and infestations10/12510/12714/126
AnaemiaBlood and lymphatic system disorders5/1257/12713/126

Baseline characteristics

Age, Continuous
Age, Continuous(Years)OCR 400 mg + SOCOCR 1000 mg + SOCPlacebo + SOCTotal
Mean31.9 ± 10.230.6 ± 8.931.3 ± 9.931.3 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)OCR 400 mg + SOCOCR 1000 mg + SOCPlacebo + SOCTotal
Female115110107332
Male12181949
Race (NIH/OMB)
Race (NIH/OMB)(Participants)OCR 400 mg + SOCOCR 1000 mg + SOCPlacebo + SOCTotal
American Indian or Alaska Native17151749
Asian392735101
Native Hawaiian or Other Pacific Islander0000
Black or African American77519
White556758180
More than one race0000
Unknown or Not Reported9121132
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2008 to primary completion in Oct 2009, 20 months.

Results were first posted in Dec 2020, 11 years 2 months after primary completion. A results delay was requested in Mar 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2008
First posted
Feb 29, 2008
StartActual
Feb 15, 2008
Primary completionActual
Oct 19, 2009
CompletionActual
Oct 28, 2013
Results delay requested
Mar 17, 2016
Results first posted
Dec 22, 2020
Last update
Dec 22, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00626197
Lead sponsor
Genentech, Inc.
Collaborators
Roche Pharma AG
Responsible party
Sponsor
First posted
Feb 29, 2008
Start date
Feb 15, 2008
Primary completion
Oct 19, 2009
Completion
Oct 28, 2013
Results posted
Dec 22, 2020
Last update
Dec 22, 2020

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ocrelizumab

Start the discussion